Harbour BioMed Receives NMPA IND Clearance for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease
Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and ...
Morningstar3d
Harbour BioMed Receives NMPA IND Clearance for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 4, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company ...
Pharmabiz2d
China NMPA clears Harbour BioMed’s IND application for HBM9378/SKB378 for chronic obstructive pulmonary disease treatment
Cambridge, Massachusetts Thursday, February 6, 2025, 13:00 Hrs [IST] ...
Mena FN29d
Harbour Biomed Announces License Agreement With Windward Bio For HBM9378/SKB378, An Anti-TSLP Fully Human Antibody For Immunological Diseases
Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune ...
Longview News-Journal29d
Harbour BioMed Announces License Agreement with Windward Bio for HBM9378/SKB378, an Anti-TSLP Fully Human Antibody for Immunological Diseases
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on immunology and oncology.